ASLAN Pharmaceuticals and Zenyaku Kogyo have recently entered into a strategic licensing agreement. Under this agreement, ASLAN Pharmaceuticals has granted Zenyaku Kogyo exclusive rights to develop and commercialize eblasakimab in Japan. As part of the strategic licensing agreement between ASLAN Pharmaceuticals and Zenyaku Kogyo, ASLAN is set to receive up to $15 million in upfront and near-term payments. In addition to this initial payment, ASLAN may also be eligible to receive milestone payments based on specific developmental and commercial achievements related to eblasakimab in Japan. The collaboration between ASLAN Pharmaceuticals and Zenyaku Kogyo represents a significant expansion of dermatology portfolio, particularly in the treatment of moderate-to-severe atopic dermatitis (AD). Based on the positive data to date, Eblasakimab, with its unique mechanism of action, offers the potential for a safe, effective, and convenient therapeutic option for patients with AD. Eblasakimab is a potential first-in-class monoclonal antibody that targets the IL-13 receptor subunit of the Type 2 receptor.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!